Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir.
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
01 08 2020
01 08 2020
Historique:
received:
24
09
2019
revised:
28
02
2020
accepted:
18
03
2020
pubmed:
4
5
2020
medline:
25
6
2021
entrez:
4
5
2020
Statut:
ppublish
Résumé
Cabotegravir is an HIV integrase inhibitor in clinical development with both oral and long-acting (LA) injectable formulations. Cabotegravir is primarily metabolized by uridine 5'-diphospho-glucuronosyltransferase (UGT) 1A1, a known polymorphic enzyme with functional variants that can affect drug metabolism and exposure. To investigate the pharmacogenetic effects of the reduced-function alleles UGT1A1*6, UGT1A1*28 and/or UGT1A1*37 on steady-state pharmacokinetics (PK) and safety of oral cabotegravir (30 mg/day) and intramuscular cabotegravir LA (400 mg every 4 weeks or 600 mg every 8 weeks). Plasma cabotegravir PK was assessed in 346 UGT-genotyped participants with and without UGT1A1 functional variants across six studies (four Phase I and two Phase II) of oral cabotegravir, including 215 HIV-infected participants who received oral cabotegravir followed by cabotegravir LA. Changes from baseline in total bilirubin and ALT were assessed in one study (LATTE; NCT01641809). Statistically significant (P < 0.05) associations were observed between UGT1A1 genotype and plasma cabotegravir PK parameters, with 28%-50% increases following oral cabotegravir [plasma cabotegravir concentration at the end of the dosing interval (Ctau), 1.50-fold; AUCtau, 1.41-fold; and Cmax, 1.28-fold] and 16%-24% increases following cabotegravir LA administration (48 week Ctau, 1.24-fold; AUCtau, 1.16-fold; and Cmax, 1.18-fold) among those with low-versus-normal genetically predicted UGT1A1 activity. A statistically significant (P < 10-5) association between predicted UGT1A1 activity and maximum change in total bilirubin was also observed (2.45-fold asymptomatic increase for low versus normal) without a corresponding change in ALT. This modest increase in oral and parenteral cabotegravir exposure associated with a reduced function of UGT1A1 is not considered clinically relevant based on accumulated safety data; no dose adjustment is required.
Sections du résumé
BACKGROUND
Cabotegravir is an HIV integrase inhibitor in clinical development with both oral and long-acting (LA) injectable formulations. Cabotegravir is primarily metabolized by uridine 5'-diphospho-glucuronosyltransferase (UGT) 1A1, a known polymorphic enzyme with functional variants that can affect drug metabolism and exposure.
OBJECTIVES
To investigate the pharmacogenetic effects of the reduced-function alleles UGT1A1*6, UGT1A1*28 and/or UGT1A1*37 on steady-state pharmacokinetics (PK) and safety of oral cabotegravir (30 mg/day) and intramuscular cabotegravir LA (400 mg every 4 weeks or 600 mg every 8 weeks).
METHODS
Plasma cabotegravir PK was assessed in 346 UGT-genotyped participants with and without UGT1A1 functional variants across six studies (four Phase I and two Phase II) of oral cabotegravir, including 215 HIV-infected participants who received oral cabotegravir followed by cabotegravir LA. Changes from baseline in total bilirubin and ALT were assessed in one study (LATTE; NCT01641809).
RESULTS
Statistically significant (P < 0.05) associations were observed between UGT1A1 genotype and plasma cabotegravir PK parameters, with 28%-50% increases following oral cabotegravir [plasma cabotegravir concentration at the end of the dosing interval (Ctau), 1.50-fold; AUCtau, 1.41-fold; and Cmax, 1.28-fold] and 16%-24% increases following cabotegravir LA administration (48 week Ctau, 1.24-fold; AUCtau, 1.16-fold; and Cmax, 1.18-fold) among those with low-versus-normal genetically predicted UGT1A1 activity. A statistically significant (P < 10-5) association between predicted UGT1A1 activity and maximum change in total bilirubin was also observed (2.45-fold asymptomatic increase for low versus normal) without a corresponding change in ALT.
CONCLUSIONS
This modest increase in oral and parenteral cabotegravir exposure associated with a reduced function of UGT1A1 is not considered clinically relevant based on accumulated safety data; no dose adjustment is required.
Identifiants
pubmed: 32361755
pii: 5828323
doi: 10.1093/jac/dkaa147
pmc: PMC7366207
doi:
Substances chimiques
HIV Integrase Inhibitors
0
Pyridones
0
Glucuronosyltransferase
EC 2.4.1.17
cabotegravir
HMH0132Z1Q
Banques de données
ClinicalTrials.gov
['NCT01641809']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2240-2248Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
Références
Blood. 2005 Feb 1;105(3):968-72
pubmed: 15388579
Br J Cancer. 2010 Apr 27;102(9):1371-7
pubmed: 20389299
Clin Pharmacokinet. 2018 Oct;57(10):1325-1336
pubmed: 29654492
Pharmacogenetics. 1999 Oct;9(5):591-9
pubmed: 10591539
Pharmacogenetics. 2004 May;14(5):329-32
pubmed: 15115919
Pharmacogenomics. 2014 Jan;15(1):9-16
pubmed: 24329186
Pharmacogenet Genomics. 2014 Mar;24(3):177-83
pubmed: 24492252
Antivir Ther. 2019;24(4):301-308
pubmed: 30896438
Oncol Lett. 2016 Nov;12(5):4231-4237
pubmed: 27895797
PLoS One. 2012;7(4):e33988
pubmed: 22514612
Biochim Biophys Acta. 1998 Apr 28;1406(3):267-73
pubmed: 9630669
Lancet HIV. 2017 Aug;4(8):e331-e340
pubmed: 28546090
Clin Cancer Res. 2010 Aug 1;16(15):3832-42
pubmed: 20562211
Pharmacol Ther. 2014 Jan;141(1):92-116
pubmed: 24076267
Xenobiotica. 2016;46(5):445-56
pubmed: 26340566
Cancer Chemother Pharmacol. 2011 Jan;67(1):237-41
pubmed: 20814789
Lancet. 2017 Sep 23;390(10101):1499-1510
pubmed: 28750935
Xenobiotica. 2016;46(2):147-62
pubmed: 26134155
Hum Mutat. 2010 Jan;31(1):52-9
pubmed: 19830808
Curr Clin Pharmacol. 2010 Aug;5(3):209-17
pubmed: 20406168
Drug Metab Dispos. 2012 Mar;40(3):539-55
pubmed: 22180047
N Engl J Med. 1995 Nov 2;333(18):1171-5
pubmed: 7565971
Int J Clin Oncol. 2009 Apr;14(2):136-42
pubmed: 19390945
Biochem Mol Biol Int. 1998 Sep;46(1):21-6
pubmed: 9784835
Hum Mutat. 2000 Oct;16(4):297-306
pubmed: 11013440
Pharmacogenomics J. 2004;4(1):49-53
pubmed: 14647407
Lancet Infect Dis. 2015 Oct;15(10):1145-1155
pubmed: 26201299
Pharmacogenomics. 2013 Apr;14(5):541-54
pubmed: 23556451
Pharmacogenet Genomics. 2006 May;16(5):321-9
pubmed: 16609363
Blood. 2004 Jan 1;103(1):67-72
pubmed: 12969965
Antimicrob Agents Chemother. 2013 Nov;57(11):5472-7
pubmed: 23979733
Pharmacogenomics. 2008 Jun;9(6):703-15
pubmed: 18518849
Hepatology. 2006 Nov;44(5):1324-32
pubmed: 17058217
Drug Metab Dispos. 2013 Feb;41(2):353-61
pubmed: 23132334
Curr Opin HIV AIDS. 2015 Jul;10(4):239-45
pubmed: 26049948
J Clin Invest. 1994 Dec;94(6):2385-91
pubmed: 7989595
Xenobiotica. 2012 Mar;42(3):266-77
pubmed: 21995321
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8170-4
pubmed: 9653159
J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):487-92
pubmed: 25473882
Br J Clin Pharmacol. 2009 Apr;67(4):437-44
pubmed: 19371317
Ann Oncol. 2013 Nov;24(11):2927-8
pubmed: 24107802